FlowSync Solutions Ltd is developing a groundbreaking solution to address the critical issue of fluid management in surgical and acute care settings using a novel automated system. Flowmaster 1.0 is designed to track fluid balance in patients with precision, the device provides real-time data to prevent complications such as fluid overload and dehydration.
To solidify their commercial strategy and secure the necessary capital for mid-stage prototype development, FlowSync Solutions Ltd required a comprehensive understanding of the global market landscape, a robust funding strategy, and a clear roadmap for navigating the complex NHS procurement process.
The Technology
Accurate fluid balance monitoring is vital for patient safety after surgical procedures, as well as for critically ill patients in ICUs. Currently, fluid management often relies on nurses providing manual tracking, which can be prone to error and is time-consuming where a single nurse will be responsible for chart updates on multiple patients. Any mistakes in the subsequent calculations that are performed to determine fluid balance can lead to risks of undetected fluid overload (pulmonary oedema) or dehydration.
The Flowmaster 1.0 is an automated fluid management system that continuously monitors fluid intake and output. By providing accurate, real-time data, it empowers clinicians to detect imbalances immediately, significantly improving patient safety and reducing the burden on nursing staff. The technology aims to replace manual fluid charts with a digital, precision-based approach that integrates seamlessly into existing clinical workflows.
Supported with grant funding from Innovate UK Business Growth, FlowSync Solutions Ltd partnered with Health Tech Enterprise (HTE) to build a solid commercial foundation for their technology. Our tailored approach included:
- Global Market Assessment: A detailed analysis of the market size and competitor landscape, identifying that in the UK alone, approximately 28,500 patients in acute NHS Trusts are catheterised daily. This assessment segmented opportunities by clinical specialty to identify high-priority entry points.
- Grant Funding Roadmap: The development of a strategic roadmap prioritizing high-potential UK and EU funding streams (such as Innovate UK and the EIC Accelerator). This included specific guidance on application timing and the necessary evidence base to secure non-dilutive funding.
- NHS Procurement Strategy: The creation of a practical implementation guide detailing NHS supply chain frameworks, value-based procurement criteria, and the engagement steps required to secure clinical adoption and reimbursement.
Outcomes
The strategic guidance provided by Health Tech Enterprise has equipped FlowSync Solutions Ltd with the independent validation and commercial intelligence needed to advance their innovation. The project:
- Confirmed Market Opportunity: Delivered quantified insights into the total addressable market and specific high-yield clinical segments, allowing the company to prioritize its R&D resources effectively.
- Secured Funding Pathways: Provided a clear, prioritized roadmap for grant applications, significantly de-risking the fundraising process and preparing the company for investor engagement.
- Clarified Market Access: Demystified the route to NHS adoption, equipping FlowSync Solutions Ltd with an actionable plan to engage procurement leads and clinical champions, accelerating their path to market.
“The strategic guidance we received was instrumental in confirming the commercially viability of the FlowSync Solutions Ltd innovation. The detailed market assessment and the customized Grant Funding Roadmap provided in combination with the NHS Procurement Guide has given us clarity on the route to adoption, allowing us to align our strategy with clinical realities and significantly de-risk our path to market.”
— Tahir Nasser, CEO, FlowSync Solutions Ltd
